Salvador Fonseca Reyes

Changes in the Costs of Antihypertensive Medications in a Developing Country A Study in Mexico Comparing 1990 and 1996

In developing countries, the cost of antihypertensive medications is one of the principal limiting factors when trying to treat patients with high blood pressure. To determine the changes in cost (in US dollars) of these medications and in the percentage of the minimum wage needed to purchase them, two cost studies (1990 and 1996) done in Mexico were compared. The yearly cost of a treatment with hydrochlorothiazide was US

Diagnóstico y tratamiento de la crisis hipertensiva

13.80 in 1990; in 1996 it was US

Changes in the Costs of Antihypertensive Medications in a Developing Country

10.92. Both figures represent 1.1% of the minimum wage that was in effect at the time. Propranolol hydrochloride cost US

Recomendaciones para el tratamiento de la hipertensión en adultos

50.52 for a years treatment in 1990, and US

Se reporta el caso de un paciente con abscesos hepáticos múltiples debidos a S. constellatus, tratado inicialmente con antibióticos y aspiración percutánea pero que posteriormente requirió drenaje quirúrgico en tres ocasiones. Palabras clave: Streptococcus constellatus, Streptococcus del grupo milleri, abscesos hepáticos piógenos.

66.12 for the same in 1996. These figures represented, respectively, 4.2% and 6.7% of the minimum wage of 1990 and 1996. The annual cost for nifedipine was US

Streptococcus constellatus y múltiples abscesos hepáticos. Reporte de un caso

176.76 in 1990 (14.7% of the minimum wage) and US

Disfunción diastólica en pacientes con hipertensión de bata blanca

242.16 in 1996 (24.8% of the minimum wage). The yearly cost of enalapril was US

Medición ambulatoria de la tensión arterial. Su utilidad en la clínica

233.04 in 1990 and US

Investigación en Salud

433.20 in 1996; these costs represented, respectively, 19.4% and 44.2% of the minimum wage. The comparison of these two cost studies (1990 and 1996) shows why Mexicos population is finding it more difficult to purchase antihypertensive medications. Higher costs and reduced purchasing power seem to be the two principal factors causing this. This is probably affecting the populations health, as it is more difficult to control high blood pressure without proper treatment.